Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Dipeptidyl peptidase IV (DPP IV) inhibitors: a newly emerging drug class for the treatment of type 2 diabetes
In clinical trials DPP IV inhibitors (or ‘gliptins’) have shown efficacy and tolerability in the management of hyperglycaemia in type 2 diabetes, without causing weight gain or hypoglycaemia. Expand
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1.
- B. Green, N. Irwin, N. Duffy, V. Gault, F. O'Harte, P. Flatt
- European journal of pharmacology
- 10 October 2006
Findings indicate that metformin decreases the plasma DPP IV activity, limiting the inactivation of exogenously administered GLP-1 and improving glycaemic control. Expand
Characterization of a Novel Glucose-Responsive Insulin-Secreting Cell Line, BRIN-BD11, Produced by Electrofusion
High-performance liquid chromatography analysis demonstrated that insulin was the major product secreted under stimulatory conditions, and western blotting confirmed that BRIN-BD11 cells expressed the GLUT2 glucose transporter, confirming an intact glucose sensing mechanism. Expand
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet.
- P. McClean, N. Irwin, R. Cassidy, J. Holst, V. Gault, P. Flatt
- Biology, Medicine
- American journal of physiology. Endocrinology and…
- 1 December 2007
Data indicate that GIP receptor antagonism using (Pro(3))GIP provides an effective means of countering obesity and related diabetes induced by consumption of a high-fat, energy-rich diet. Expand
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
- J. Lindsay, N. Duffy, +4 authors P. Bell
- Diabetic medicine : a journal of the British…
- 1 May 2005
This work investigated the acute effects of metformin on DPP IV activity in Type 2 diabetes to elucidate inhibition of DPPIV as a possible mechanism of action. Expand
Insulin-releasing and insulin-like activity of the traditional anti-diabetic plant Coriandrum sativum (coriander).
The presence of antihyperglycaemic, insulin-releasing and insulin-like activity in Coriandrum sativum is demonstrated and Sequential extraction with solvents revealed insulin-reaching activity in hexane and water fractions indicating a possible cumulative effect of more than one extract constituent. Expand
The effects of traditional antidiabetic plants on in vitro glucose diffusion
The results suggest that part of the antihyperglycemic actions of these plants may be by decreasing glucose absorption in vivo. Expand
Soluble dietary fibre fraction of Trigonella foenum-graecum (fenugreek) seed improves glucose homeostasis in animal models of type 1 and type 2 diabetes by delaying carbohydrate digestion and…
- J. Hannan, L. Ali, +4 authors Y. Abdel-Wahab
- Medicine, Biology
- British Journal of Nutrition
- 1 March 2007
The present findings indicate that the SDF fraction of T. foenum-graecum seeds exerts antidiabetic effects mediated through inhibition of carbohydrate digestion and absorption, and enhancement of peripheral insulin action. Expand
Potential therapeutic applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-viral, immunomodulatory, and anti-diabetic agents
This review assesses the therapeutic possibilities of peptides from frogs belonging to the Ascaphidae, Alytidae, Pipidae, Dicroglossidae, Leptodactylidae, Hylidae and Ranidae families that complement their potential role as anti-infectives for use against multidrug-resistant microorganisms. Expand
Therapeutic potential for GIP receptor agonists and antagonists.
The therapeutic potential of GIP-based therapeutics in the treatment of type 2 diabetes and obesity is highlighted and longer-acting GIP agonists exhibiting enzymatic stability and enhanced bioactivity are generated and successfully tested in animal models of diabetes. Expand